Tekla Life Sciences Investors Paid Distribution

Editorial & Advertiser Disclosure Global Banking And Finance Review is an independent publisher which offers News, information, Analysis, Opinion, Press Releases, Reviews, Research reports covering various economies, industries, products, services and companies. The content available on globalbankingandfinance.com is sourced by a mixture of different methods which is not limited to content produced and supplied by various staff writers, journalists, freelancers, individuals, organizations, companies, PR agencies Sponsored Posts etc. The information available on this website is purely for educational and informational purposes only. We cannot guarantee the accuracy or applicability of any of the information provided at globalbankingandfinance.com with respect to your individual or personal circumstances. Please seek professional advice from a qualified professional before making any financial decisions. Globalbankingandfinance.com also links to various third party websites and we cannot guarantee the accuracy or applicability of the information provided by third party websites. Links from various articles on our site to third party websites are a mixture of non-sponsored links and sponsored links. Only a very small fraction of the links which point to external websites are affiliate links. Some of the links which you may click on our website may link to various products and services from our partners who may compensate us if you buy a service or product or fill a form or install an app. This will not incur additional cost to you. A very few articles on our website are sponsored posts or paid advertorials. These are marked as sponsored posts at the bottom of each post. For avoidance of any doubts and to make it easier for you to differentiate sponsored or non-sponsored articles or links, you may consider all articles on our site or all links to external websites as sponsored . Please note that some of the services or products which we talk about carry a high level of risk and may not be suitable for everyone. These may be complex services or products and we request the readers to consider this purely from an educational standpoint. The information provided on this website is general in nature. Global Banking & Finance Review expressly disclaims any liability without any limitation which may arise directly or indirectly from the use of such information.

On June 30, 2020, Tekla Life Sciences Investors paid a distribution of $0.34 per share. It is currently estimated that this distribution is derived from net realized short-term capital gains and net realized long-term capital gains. The composition of this and subsequent distributions may vary from quarter to quarter because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized gains on sale of securities is $163,698,946, of which $144,824,655 represents net unrealized appreciation of portfolio securities.

The following table sets forth the estimated amounts of the current distribution, paid on June 30, 2020, and the cumulative distributions paid this fiscal year-to-date from the following sources: net investment income, net realized short-term capital gains, net realized long-term capital gains, return of capital or other capital source.

Current Distribution

Percentage Breakdown of Current Distribution

Total Cumulative Distributions for the Fiscal Year to Date1

Percentage Breakdown of the Total Cumulative Distributions for the Fiscal Year to Date1

Net Investment Income





Net Realized ST Cap Gains





Net Realized LT Cap Gains





Return of Capital or Other Capital Source





TOTAL (per common share):










The table below includes information relating to the Funds performance based on its NAV for certain periods.






Average annual return at NAV for the period from April 30, 2015 through April 30, 2020


Annualized current distribution rate expressed as percentage of NAV as of April 30, 2020


Cumulative total return at NAV for the fiscal year, through April 30 20202


Cumulative fiscal year-to-date distribution rate expressed as a percentage of NAV as of April 30, 20201


You should not draw any conclusions about the Funds investment performance from the amount of this distribution or from the terms of the Funds managed distribution policy.

The amounts and sources of distributions reported in this press release are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Funds investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions for federal income tax purposes.

Tekla Life Sciences Investors (NYSE: HQL) is a closed-end fund that invests in companies in the healthcare industry.

Tekla Capital Management LLC, the Funds investment adviser, is a Boston, MA based healthcare-focused investment manager with approximately $2.7 billion of net assets under management as of March 31, 2020. Tekla also serves as investment adviser to Tekla Healthcare Investors (NYSE: HQH), Tekla Healthcare Opportunities Fund (NYSE: THQ) and Tekla World Healthcare Fund (NYSE: THW), closed-end funds that invest in companies in the healthcare and life sciences industries. Information regarding the Funds and Tekla Capital Management LLC can be found at www.teklacap.com.

Destra Capital Investments is the Funds marketing and investor support services agent. Please contact Destra Capital Investments at [email protected] or call (877) 855-3434 if you have any questions regarding HQL.

1 The Funds current fiscal year began on October 1, 2019. 2 Cumulative total return at NAV is the percentage change in the Funds NAV and includes all distributions and assumes the reinvestment of those distributions for the period of September 30, 2019 through April 30, 2020.

Destra Capital Investments

(877) 855-3434

[email protected]